Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perspective Therapeutics, Inc. (CATX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Perspective is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer, and its filings offer detail on clinical progress, financial condition, and corporate governance.
Recent Form 8-K reports referenced in the input data include announcements of updated corporate presentations, interim clinical results from the Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, and quarterly financial results with business highlights. Other 8-K filings describe executive leadership changes, such as the appointment of a new Chief Financial Officer and amended and restated employment agreements for senior executives, including change-in-control and severance terms.
Through this page, users can review Perspective’s current and historical 8-Ks and, when available, its periodic reports such as Forms 10-K and 10-Q, which typically contain audited or reviewed financial statements, segment information, and risk factor disclosures. These documents help clarify how the company funds its clinical programs, how it accounts for research and development and general and administrative expenses, and how it describes its radiopharmaceutical platform and manufacturing infrastructure enabled by its proprietary 212Pb generator.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major clinical updates, financial trends, and governance changes. Real-time ingestion from EDGAR, along with structured access to items such as executive compensation arrangements and other material contracts, supports deeper analysis of CATX’s regulatory and corporate history.
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics (CATX) amended and restated employment agreements for its CEO Johan (Thijs) Spoor, Chief Accounting Officer Jonathan Hunt, and Chief Medical Officer Dr. Markus Puhlmann. The updates reflect current base salaries and revise change-in-control provisions.
Base salaries are $680,000 for Mr. Spoor, $451,500 for Mr. Hunt, and $516,700 for Dr. Puhlmann. If employment ends without cause or for good reason during the three months before or 12 months after a change in control, severance includes salary continuation for 12 months (18 months for Mr. Spoor), a pro‑rated target bonus, an additional amount equal to the target bonus (1.5x target for Mr. Spoor), and COBRA premiums for up to 12 months (18 months for Mr. Spoor).
Equity awards subject to time-based vesting accelerate to full vesting, and performance-based awards vest at target upon qualifying terminations in the protection period or if awards are not assumed, replaced, or continued at closing, subject to a release of claims. Other existing terms remain in effect.
Perspective Therapeutics (CATX) filed an 8‑K announcing a press release and presentation with updated interim results from its Phase 1/2a study of [212Pb]VMT‑α‑NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors. The data are being presented at ESMO 2025 in Berlin. The materials also include the Company’s estimated cash, cash equivalents and short‑term investments as of September 30, 2025, which are preliminary, unaudited, and subject to change.
Perspective Therapeutics insider Joel Sendek, the company's Chief Financial Officer, was granted a stock option on 09/04/2025 to purchase 600,000 shares of common stock at an exercise price of $3.54 per share. The option has an expiration date of 09/04/2035 and becomes exercisable over a four-year vesting schedule: one-fourth vests on 09/04/2026 and the remaining shares vest ratably over the following 36 months, subject to continuous service. After the grant, the reporting person beneficially owns 600,000 underlying shares through the option, held in a direct ownership form. The Form 4 was signed by attorney-in-fact on 09/05/2025.
Joel Sendek, serving as Chief Financial Officer and a director of Perspective Therapeutics, Inc. (CATX), filed an initial Form 3 reporting the 09/04/2025 event date. The filing states that the reporting person does not beneficially own any securities of the issuer. The form references Exhibit 24 (Power of Attorney) and was signed via attorney-in-fact on 09/05/2025.
Maria E. Martinez, a director of Perspective Therapeutics, Inc. (CATX), was granted 75,000 stock options on 09/03/2025 with an exercise price of $3.38. The options vest monthly over three years in 36 substantially equal installments beginning one month after the grant date, are exercisable beginning 09/03/2025, and expire on 09/03/2035. After the reported transaction the reporting person beneficially owns 75,000 shares underlying the option on a direct basis. The Form 4 was signed on behalf of Maria E. Martinez by an attorney-in-fact on 09/05/2025.
Perspective Therapeutics, Inc. (CATX) filed a Form 3 reporting Maria E. Martinez as a Director and a reporting person. The event date listed is 09/03/2025. The filing states explicitly that no securities are beneficially owned by the reporting person and references Exhibit 24 (Power of Attorney). The form is signed by Maria E. Martinez via attorney-in-fact on 09/05/2025.
Perspective Therapeutics, Inc. reported that its Board of Directors voted to increase the board size from five to six members and appointed Maya Martinez-Davis as a director, effective September 3, 2025. She will also serve on the Compensation Committee and the Nominations and Corporate Governance Committee.
Under the company’s Non-Employee Director Compensation Program, Ms. Martinez-Davis will receive an annual cash retainer of $60,000 and an initial grant of 75,000 stock options, with the grant date fair value capped at $450,000. These options vest in 36 equal monthly installments starting one month after the grant date, contingent on her continued service. The company expects her to enter into its standard indemnification agreement, and it states there are no related-party transactions requiring disclosure. A press release announcing her appointment was issued on September 3, 2025 and furnished as Exhibit 99.1.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
